Stevens Capital Management LP Grows Position in Cencora, Inc. (NYSE:COR)

Stevens Capital Management LP raised its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 30.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,186 shares of the company's stock after acquiring an additional 968 shares during the quarter. Stevens Capital Management LP's holdings in Cencora were worth $941,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of COR. LPL Financial LLC raised its holdings in Cencora by 7.6% in the 4th quarter. LPL Financial LLC now owns 188,828 shares of the company's stock worth $42,426,000 after purchasing an additional 13,417 shares during the period. Blueprint Investment Partners LLC purchased a new stake in Cencora in the fourth quarter worth about $269,000. Fox Run Management L.L.C. lifted its position in shares of Cencora by 19.2% during the 4th quarter. Fox Run Management L.L.C. now owns 3,665 shares of the company's stock valued at $823,000 after buying an additional 591 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Cencora during the 4th quarter valued at about $19,543,000. Finally, Sei Investments Co. grew its stake in shares of Cencora by 5.2% during the 4th quarter. Sei Investments Co. now owns 321,877 shares of the company's stock valued at $72,319,000 after acquiring an additional 16,039 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Price Performance

COR stock traded up $2.94 during trading on Thursday, hitting $274.33. 1,015,455 shares of the company's stock traded hands, compared to its average volume of 1,382,270. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $274.80. The stock has a market capitalization of $53.20 billion, a price-to-earnings ratio of 39.02, a P/E/G ratio of 1.31 and a beta of 0.51. The business has a fifty day simple moving average of $253.15 and a 200 day simple moving average of $240.91. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

Several equities analysts have weighed in on COR shares. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target on the stock. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company lifted their target price on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and an average target price of $280.20.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.